Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 2/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053122 | 1.00 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL6811347 | 0.97 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL6811341 | 0.97 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL30786035 | 0.94 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL30905085 | 0.92 | MME (0.55) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL31096839 | 0.92 | MME (0.56) | OPRD1OPRM1OPRK1MMELTA4H | |
| SCHEMBL11800074 | 0.92 | OPRD1 (0.60) | OPRD1OPRM1OPRK1MMELTA4H | |
| SCHEMBL30661444 | 0.92 | OPRD1 (0.70) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL1329567 | 0.91 | MME (0.67) | MMEACECPA1ACE2CTSC | |
| SCHEMBL825577 | 0.91 | MME (0.67) | MMEACECPA1ACE2CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516329-B2 | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell | K2B THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250122508-A1 | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY) (KR) | 2025-04-17 | — | — | US | disclosed |